584.4000 -10.15 (-1.71%)
NSE Apr 09, 2025 15:31 PM
Volume: 299.2K
 

584.40
-1.71%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. has lost -16.41% in the last 1 Week
More from Strides Pharma Science Ltd.
Recommended